Larimar Therapeutics Inc expected to post a loss of 31 cents a share - Earnings Preview

Larimar Therapeutics

06/08/2024 19:32

* Larimar Therapeutics Inc  LRMR.OQ   LRMR.O  is expected
to show
no change in quarterly revenue when it reports  results on
August 8 (estimated) for the period ending June 30 2024
    * 
    * ​LSEG's mean analyst estimate for Larimar Therapeutics Inc
is
for a loss of 31 cents per share. 
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 6 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Larimar
Therapeutics Inc is $25.00​, above​ its last closing price
of $7.42. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Mar. 31 2024  -0.23       -0.23      -0.27     Missed  -14.9
 Jan. 1 2024   -0.26       -0.25      -0.30     Missed  -21.3
 Sep. 30 2023  -0.21       -0.22      -0.21     Beat    6​
 Jun. 30 2023  -0.18       -0.19      -0.19     Met     2.6
 ​​Mar.        -0.25       -0.25      -0.15     Beat    39
 31 2023                                                
 Dec. 31 2022  -0.22       -0.27      -0.21     Beat    22.9​
 Sep. 30 2022  -0.30       -0.42      -0.37     Beat    11.9
 Jan. 1 0001   -0.49       -0.57      -0.47     Beat    18
 This summary was machine generated August 6 at 18:32 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)